European Biotech Gets New VC Coalition to Fund Startups

Europe's biotech industry just got a major boost that could help hundreds of startups bring their health innovations to life.

A group of leading European venture capital firms has formed the European Life Sciences Coalition to increase investments in biotech companies and push for policies that help these startups thrive. The coalition includes heavy hitters like Forbion, HealthCap, Novo Holdings, Omega Funds, and Sofinnova Partners, plus law firms Cooley and Covington & Burling.

The timing couldn't be more important. Europe has struggled to keep its best biotech companies at home because of limited funding options, especially as companies try to grow bigger. The numbers tell a striking story: of the 67 European Union biotech companies that went public in the past six years, 66 had to do so outside the EU to find enough investors.

This funding gap has been the main roadblock holding back Europe's life sciences industry, according to venture capitalists and biotech leaders. Promising companies developing new treatments and medical breakthroughs often hit a wall when they need money to expand their research or bring products to market.

The new coalition aims to change that landscape by bringing together major investors who can pool resources and coordinate their efforts. By working together instead of separately, these firms hope to create more opportunities for European biotech startups at every stage of growth.

The Ripple Effect

This coalition could spark a transformation across Europe's innovation ecosystem. More available capital means more scientists and entrepreneurs can pursue groundbreaking medical research without leaving their home countries. That keeps talent, jobs, and economic benefits in European communities.

The group also plans to advocate for smarter policies that support biotech development. When governments understand what startups need to succeed, they can create regulations and incentives that help rather than hinder innovation. That policy work could make Europe's biotech sector more competitive with the United States and Asia.

For patients worldwide, a stronger European biotech industry means more teams working on new treatments, drugs, and medical technologies. More competition and collaboration across borders accelerates the pace of discovery and brings life saving innovations to market faster.

The coalition represents a recognition that Europe's scientific talent deserves better financial infrastructure to succeed, and these investors are stepping up to build it.